Organ Transplant Immunosuppressant Drugs Market to reach USD 4.4 Billion by 2020

MARYLAND HEIGHTS, Mo. - June 24, 2016 - PRLog -- According to a market research report published by iHealthcareAnalyst, Inc., Organ Transplant Immunosuppressant Drugs Market - Global Immunosuppressant Drug Classes and Organ Types Analysis and Forecast 2013-2020 (http://www.ihealthcareanalyst.com/report/organ-transplant-immunosuppressant-drugs-market/), the global organ transplant immunosuppressant drugs market is estimated to reach USD 4.4 Billion by 2020 due to high incidence organ failure and physical disabilities.

Browse Organ Transplant Immunosuppressant Drugs Market - Global Immunosuppressant Drug Classes and Organ Types Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/organ-transplant-immunosuppressant-drugs-market/

Immunosuppressant drugs or anti-rejection drugs are a class of drugs that suppress or reduce the strength of the body's immune system. There are 2 types of immunosuppressants: Induction drugs: Powerful antirejection medicine used at the time of transplant and Maintenance drugs: antirejection medications used for the long term. There are usually four classes of maintenance drugs: calcineurin inhibitors: tacrolimus and cyclosporine, antiproliferative agents: mycophenolate mofetil, mycophenolate sodium and azathioprine, mTOR inhibitor: sirolimus, and steroids: prednisone. The global organ transplant immunosuppressant drugsmarket report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes and transplanted organ types (bone marrow, heart, kidney liver and lung transplants), and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global organ transplant immunosuppressant drugs market is segmented as:

1.      Drug Class

1.1.    Antibodies

1.2.   Antiproliferative Agents

1.3.   Calcineurin Inhibitors

1.4.  mTOR Inhibitors

1.5.   Steroids

2.     Organ Type

2.1.   Bone Marrow Transplant

2.2.Heart Transplant

2.3.  Kidney Transplant

2.4.Liver Transplant

2.5.  Lung Transplant

2.6.Other Transplants

3.     Geography (Region, Country)

3.1.   North America (U.S., Canada)

3.2.  Latin America (Brazil, Mexico, Rest of LA)

3.3.  Europe (U.K., Germany, France, Italy, Spain, Rest of EU)

3.4.Asia Pacific (Japan, China, India, Rest of APAC)

3.5.  Rest of the World

4.    Company Profiles

4.1.  AbbVie, Inc.

4.2.Allergan plc.

4.3.Astellas Pharma, Inc.

4.4.Bristol-Myers Squibb Company

4.5.  F. Hoffmann-La Roche Ltd.

4.6.GlaxoSmithKline plc

4.7.  Janssen Pharmaceutical

4.8.Novartis AG

4.9.Pfizer, Inc.

4.10.          Sanofi S.A.

4.11.          Veloxis Pharmaceuticals

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.